Second quarter 2026 results for Aker BioMarine

10 Jul 2026 07:00 CEST

Highlights second quarter 2026:

• Q2 revenues reached USD 57.9 million, an increase of 5% year-over-year (YoY),
with adjusted EBITDA of USD 12.9 million, down 4% from the prior year.
• Human Health Ingredients delivered USD 34.1 million in revenue, up 17% YoY.
Krill oil revenues continued their momentum, up 21% YoY to USD 31.5 million.
Adjusted EBITDA increased 14% to USD 15.9 million.
• Consumer Health Products generated USD 26.4 million in revenue, down 6% YoY.
Adjusted EBITDA of USD 1.1 million, with lower revenues and gross profit
weighing on margin
• Secured a new Lysoveta supply contract worth USD 4 million in first-year
revenues
• The company won a new Superba business ranking among the company’s largest
customers

“Krill oil sales continued their strong momentum in the second quarter, with
revenues up 21% year-over-year on solid volume growth. We are also pleased to
have secured a new Lysoveta contract worth USD 4 million in first-year revenues,
in addition to a large win for Superba Krill oil, important commercial
milestones for our ingredient portfolio”, said Matts Johansen, CEO of Aker
BioMarine.

Segment performance
Human Health Ingredients grew revenues by 17% year-over-year, with krill oil
revenues up 21% to USD 31.5 million. Growth was driven mainly by solid volumes,
with price supported by product mix and a higher share of capsulated oil. Gross
margin was stable, while EBITDA margin came in slightly below last year on
higher SG&A following investments in the sales and marketing organization.
Production in Houston was lower in the quarter, impacting QHP sales negatively,
but stabilized to normal levels at quarter end.

Consumer Health Products reported revenues of USD 26.4 million, down 6%
year-over-year. Lang revenues declined 4%, driven by lower sales through key US
retail chains, while Epion continues an ongoing marketing repositioning that is
weighing on short-term revenues but is expected to be positive over time. Gross
margin came in below last year, driven by Epion, and adjusted EBITDA was lower
on reduced revenues and gross profit.

Outlook
The Human Health Ingredients segment sees continued year-over-year growth and
improved profits, supported by good underlying demand across multiple markets.
In Consumer Health Products, revenues are expected to return to modest growth.
The Understory sales process is still ongoing with advanced discussions with one
interested party. Earlier this year, the Company engaged Jefferies and Houlihan
Lokey as investment banks to support the Company in exploring certain interest
in the Human Health Ingredient business unit. The mandate related to the Human
Health Ingredient business includes exploring different alternatives and work
towards a transaction in 2026.

Attached is the quarterly presentation and report for Q2. Group reported
financial figures can be downloaded in an excel from the company’s investor
page: Investor - Analyst information

At 09:00 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor.

A replay of the presentation will be made available soon after the presentation
at the same web address.

For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.

More information:
Access the news on Oslo Bors NewsWeb site

677954_AKBM H1-report 2026_PUBLISH.pdf
677954_AKBM_Q2_2026_Presentation.pdf